Prof David Ascher is currently an NHMRC Investigator and Director of the Biotechnology Program at the University of Queensland. He is also Head of Computational Biology and Clinical Informatics at the Baker Institute.
David’s research focus is in modelling biological data to gain insight into fundamental biological processes. One of his primary research interests has been developing tools to unravel the link between genotype and phenotype, using computational and experimental approaches to understand the effects of mutations on protein structure and function. His group has developed a platform of over 40 widely used programs for assessing the molecular consequences of coding variants (>7 million hits/year).
Working with clinical collaborators in Australia, Brazil and UK, these methods have been translated into the clinic to guide the diagnosis, management and treatment of a number of hereditary diseases, rare cancers and drug resistant infections.
David has a B.Biotech from the University of Adelaide, majoring in Biochemistry, Biotechnology and Pharmacology and Toxicology; and a B.Sci(Hon) from the University of Queensland, majoring in Biochemistry, where he worked with Luke Guddat and Ron Duggleby on the structural and functional characterization of enzymes in the branched-chain amino acid biosynthetic pathway. David then went to St Vincent’s Institute of Medical Research to undertake a PhD at the University of Melbourne in Biochemistry. There he worked under the supervision of Michael Parker using computational, biochemical and structural tools to develop small molecules drugs to improve memory.
In 2013 David went to the University of Cambridge to work with Sir Tom Blundell on using fragment based drug development techniques to target protein-protein interactions; and subsequently on the structural characterisation of proteins involved in non-homologous DNA repair. He returned to Cambridge in 2014 to establish a research platform to characterise the molecular effects of mutations on protein structure and function- using this information to gain insight into the link between genetic changes and phenotypes. He was subsequently recruited as a lab head in the Department of Biochemistry and Molecular Biology at the University of Melbourne in 2016, before joining the Baker Institute in 2019 and the University of Queensland in 2021.
He is an Associate Editor of PBMB and Fronteirs in Bioinformatics, and holds honorary positions at Bio21 Institute, Cambridge University, FIOCRUZ, and the Tuscany University Network.
Dr Melinda Ashcroft is a Research Fellow on Infectious Disease Epidemiology (Climate Change) in the Faculty of Medicine at The University of Queensland (UQ). Her current research focus is on Nontuberculous mycobacteria (NTM) and how NTM infections are associated with climate change and major weather events. Previously Melinda has worked at Monash University as a Research Fellow on the Sero-epidemiology of Klebsiella spp., at the University of Melbourne as a Postdoctoral Research Fellow on the Genomic Epidemiology of Neisseria gonorrhoeae and as a Research Associate at UQ on the genomics and epigenomics of extraintestinal pathogenic Escherichia coli. Melinda was awarded a Bachelor of Applied Science (Biotechnology/Biochemistry) in 2004 from Queensland University of Technology and a Master of Biotechnology in 2013 from UQ. She then switched fields to Microbial Genomics and was awarded a PhD from UQ in 2019 for her thesis: Evolution and function of mobile genetic elements and DNA methyltransferases in extraintestinal pathogenic Escherichia coli.
Dr Sandra Brosda is a Research Fellow within the Surgical Oncology group led by Professor Andrew Barbour.
Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the University of Queensland in November 2020. Her research focused on biomarker discovery and intra-tumour heterogeneity and tumour evolution in oesophageal adenocarcinoma (OAC). In 2021, Dr Brosda was awarded a Cure Cancer Australia PdCCRS grant and an MSH project grant to further investigate tumour evolution to improve precision medicine in OAC.
She has been involved in research projects covering genetics, epigenetics, spatial transcriptomics, radiomics, ctDNA and quality of life assessments in the context of cancer. Overall, her research applies bioinformatics tools and approaches to cancer genomics to improve precision medicine and health outcomes for patients with melanoma, oesophago-gastric cancer and pancreatic cancer.
I am a developmental neuroscientist and bioinformatician interested in the molecular evolution of the mammalian brain. I completed a PhD on the molecular development of vasculature in the primate retina at the Australian National University, followed by a postdoctoral position at the Institut de la Vision in France that was supported by a NHMRC CJ Martin fellowship, where I investigated the role of guidance factors in the formation of commissural neurons within the mammalian hindbrain. My current research focuses on the development and evolution of the mammalian forebrain, in particular understanding the regulatory mechanisms and molecular evolutionary processes that control specification of cortical neuron subtypes.
